Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:CTNMNASDAQ:PHARNASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$22.20-1.2%$21.71$12.21▼$41.31$660.18M-0.26636,474 shs525,155 shsCTNMContineum Therapeutics$3.97-3.4%$4.13$3.35▼$22.00$106.33M0.5288,657 shs159,611 shsPHARPharming Group$10.68-2.9%$10.26$6.65▼$12.61$748.58M0.026,157 shs33,193 shsRCKTRocket Pharmaceuticals$2.45-3.2%$4.85$2.19▼$26.98$270.17M0.692.16 million shs3.11 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.20%-2.72%-1.11%+20.65%-11.41%CTNMContineum Therapeutics-3.41%-3.64%+9.67%-38.54%-77.46%PHARPharming Group-1.39%+1.82%-2.01%+28.47%+27.86%RCKTRocket Pharmaceuticals-3.16%-6.84%-1.21%-57.83%-88.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio2.2801 of 5 stars3.41.00.00.03.21.70.6CTNMContineum Therapeutics2.1531 of 5 stars3.61.00.00.01.80.81.3PHARPharming Group3.1443 of 5 stars3.55.00.00.03.40.00.6RCKTRocket Pharmaceuticals4.9085 of 5 stars4.22.00.04.72.85.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3890.88% UpsideCTNMContineum Therapeutics 3.17Buy$22.50466.75% UpsidePHARPharming Group 3.00Buy$30.00181.00% UpsideRCKTRocket Pharmaceuticals 2.41Hold$18.60659.18% UpsideCurrent Analyst Ratings BreakdownLatest CTNM, PHAR, RCKT, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025CTNMContineum TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform6/17/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.006/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.006/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $11.005/30/2025RCKTRocket PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ In-Line$5.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/28/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/28/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $9.005/28/2025RCKTRocket PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M7.15N/AN/A$2.33 per share9.53CTNMContineum Therapeutics$50M2.05N/AN/A$7.66 per share0.52PHARPharming Group$297.20M2.44$0.07 per share148.44$3.25 per share3.28RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)CTNMContineum Therapeutics-$42.26M-$1.97N/AN/AN/AN/A-24.59%-23.49%8/12/2025 (Estimated)PHARPharming Group-$11.84M-$0.20N/A355.87N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)Latest CTNM, PHAR, RCKT, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.258.25CTNMContineum TherapeuticsN/A21.4721.47PHARPharming Group0.392.762.00RCKTRocket Pharmaceuticals0.059.199.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACTNMContineum TherapeuticsN/APHARPharming Group0.03%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CTNMContineum Therapeutics11.30%PHARPharming Group2.07%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million19.54 millionOptionableCTNMContineum Therapeutics3125.87 million22.95 millionN/APHARPharming Group28068.03 million66.62 millionNot OptionableRCKTRocket Pharmaceuticals240106.79 million80.35 millionOptionableCTNM, PHAR, RCKT, and ANAB HeadlinesRecent News About These CompaniesInvestors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT1 hour ago | prnewswire.comRocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens BermanJune 30 at 1:06 PM | globenewswire.comROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming DeadlineJune 30 at 12:30 PM | globenewswire.comThe Gross Law Firm Reminds Rocket Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKTJune 30 at 9:00 AM | prnewswire.comRocket Classic purse: How much can PGA Tour golfers make?June 30 at 2:46 AM | indystar.comIThe Rocket Classic will have a new spot on the PGA Tour schedule in 2026June 30 at 2:46 AM | msn.comRocket Classic 2025 leaderboard: Final results and scores from Detroit Golf ClubJune 30 at 2:46 AM | msn.comAldrich Potgieter wins Rocket Classic after outlasting Max Greyserman, Chris KirkJune 29 at 8:46 PM | msn.comRocket Classic notes: Is DGC about to become a par 70 for the PGA Tour?June 29 at 8:46 PM | detroitnews.comD2025 Rocket Classic live updates: Max Greyserman, Aldrich Potgieter on fifth playoff holeJune 29 at 8:46 PM | msn.comAldrich Potgieter wins Rocket Classic on 5th playoff hole, outlasting Max Greyserman and Chris KirkJune 29 at 8:46 PM | msn.comAldrich Potgieter, 20, survives 'tough day,' emerges as Rocket champ in five-hole playoffJune 29 at 8:46 PM | detroitnews.comDRocket Classic 2025: Aldrich Potgieter survives wild three-man playoff to win in DetroitJune 29 at 8:46 PM | msn.comSovran Advisors LLC Purchases 172,324 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)June 29 at 6:41 AM | marketbeat.comRocket Lab launches second Electron within 48 hoursJune 28 at 2:28 PM | spacenews.comSRocket Lab launches 'Symphony of the Stars' missionJune 28 at 2:28 PM | msn.com2025 Rocket Classic TV schedule, coverage, channel, golf live stream, where to watch PGA Tour eventJune 28 at 2:28 PM | cbssports.comWhat is the cut line at Rocket Classic? Who made and missed the cut?June 28 at 2:28 PM | msn.comRocket Classic 2025: Third round live leaderboard updates, tee times, how to watchJune 28 at 2:28 PM | jsonline.comJ2025 Rocket Classic leaderboard live updates: Golf scores, coverage in Round 3 with Collin Morikawa contendingJune 28 at 2:28 PM | cbssports.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKTJune 28 at 10:00 AM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsCTNM, PHAR, RCKT, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$22.20 -0.27 (-1.20%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$21.95 -0.25 (-1.14%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Contineum Therapeutics NASDAQ:CTNM$3.97 -0.14 (-3.41%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$3.99 +0.02 (+0.53%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Pharming Group NASDAQ:PHAR$10.68 -0.32 (-2.95%) As of 06/30/2025 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Rocket Pharmaceuticals NASDAQ:RCKT$2.45 -0.08 (-3.16%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$2.44 -0.01 (-0.20%) As of 09:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
